Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.13.

A number of research analysts have recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research report on Monday, November 18th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Sutro Biopharma in a research note on Tuesday, December 10th. Piper Sandler reissued an “overweight” rating and set a $11.00 target price on shares of Sutro Biopharma in a research note on Friday, October 11th. Finally, Wells Fargo & Company reduced their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently added to or reduced their stakes in STRO. Gladius Capital Management LP bought a new position in Sutro Biopharma in the third quarter worth approximately $28,000. ProShare Advisors LLC increased its holdings in shares of Sutro Biopharma by 49.1% in the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after acquiring an additional 5,373 shares during the period. Virtu Financial LLC bought a new position in shares of Sutro Biopharma in the 3rd quarter worth $77,000. Intech Investment Management LLC purchased a new stake in shares of Sutro Biopharma during the 3rd quarter worth $91,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Sutro Biopharma by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after purchasing an additional 7,082 shares during the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Trading Up 3.3 %

STRO stock opened at $1.88 on Monday. Sutro Biopharma has a 12 month low of $1.70 and a 12 month high of $6.13. The stock has a market cap of $155.02 million, a PE ratio of -1.17 and a beta of 1.09. The company has a 50-day moving average price of $3.10 and a 200 day moving average price of $3.54.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.